Advertisement
Passage Bio Says New Interim Data From Imagine-1 Clinical Study Strengthens Safety Profile Of PBGM01
(RTTNews) - Genetic medicines company Passage Bio, Inc. (PASG) announced on Wednesday new interim safety, biomarker, and clinical development results from cohorts 1-3 in the Imagine-1 clinical study.
Imagine-1 is a Phase 1/2, global, open-label, dose-escalation study of the AAVhu68 gene therapy PBGM01 delivered by intra-cisterna magna (ICM) injection in four cohorts of pediatric subjects with early and late infantile GM1 Gangliosidosis (GM1).
GM1 is a rare, fatal lysosomal storage disease in which mutations in the GLB1 gene result in very low activity of the enzyme beta-galactosidase (ß-Gal).
The interim data include six treated patients from the first three cohorts. Cohort 1 (late infantile, low dose), Cohort 2 (late infantile, high dose) and Cohort 3 (early infantile, low dose) each consisted of two patients. Cohort 4 (early infantile, high dose) patients have been dosed and data is expected by mid-2023.
The company noted that new interim data from cohorts 1-3 continue to strengthen the favorable safety profile of PBGM01, with no treatment-related serious adverse events, no complications related to ICM administration and no evidence of DRG toxicity.
Passage has completed dosing of PBGM01 in the dose-escalation portion of the study and will evaluate dosing further patients at the current high dose and/or a higher dose as data from cohorts 1-4 mature.
For More Such Health News, visit rttnews.com
Thai Central Bank Cuts Rate By 25 Bps
Yen Falls On Trade Deal Hopes
UK Stocks Turning In Mixed Performance; FTSE 100 Up Marginally At Noon
Yen Falls Against Majors
CAC 40 Up Over 0.5% As Stocks Move Higher On Results, Easing Trade Tensions
Australian Dollar Rises On CPI Data
Sensex, Nifty End Choppy Session Marginally Lower
